Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.20
Views: 215

Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Jonathan Rosenberg speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the preliminary durability results of the EV-103 study of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

He reports that there was an updated response rate of 73% for untreated patients, which is exceedingly high for what we expect for these patients, and that the median progression free survival was 12.3 months.

Dr Rosenberg also mentions that the side effects profile is not too dissimilar to either drug by itself sand that there does not seem to be synergistic toxicities.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation